United States· US:39892-0830_40b405f4-b084-33f2-e063-6294a90a1027
MediChoice Triple Antibiotic
A medicinal product containing bacitracin; neomycin sulfate; polymyxin b sulfate, registered in United States by O&M HALYARD, INC..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
- Manufacturer
- O&M HALYARD, INC.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc113989208301144 PACKET in 1 CARTON (39892-0830-1) / .9 g in 1 PACKET
- ndc1139892-0830-1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5774ef49-d4c9-48eb-b5fa-c4e823f2b8bf GET /v1/drugs/5774ef49-d4c9-48eb-b5fa-c4e823f2b8bf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "TOPICAL",
"source": "ndc",
"strength": "400; 5; 5000",
"substance": "BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE",
"productndc": "39892-0830",
"dosage_form": "OINTMENT",
"dea_schedule": null,
"strength_unit": "[iU]/g; mg/g; [iU]/g",
"application_number": "M004",
"marketing_category": "OTC MONOGRAPH DRUG"
}See everything about bacitracin; neomycin sulfate; polymyxin b sulfate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.